Show Me the Data™: Incorporating the Latest Advances in Immunotherapy and EGFR-Targeted Treatments for Resectable, Early-Stage NSCLC

Release Date: February 10, 2026

Expiration Date: February 10, 2027

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in early-stage, resectable, non–small cell lung cancer (NSCLC). In this educational program, these experts lead case-based panel discussions on the latest clinical advances in managing resectable NSCLC with immunotherapy and targeted treatments. The expert panel also shares their perspectives on the latest data and clinical pearls from their practices in managing early-stage, resectable NSCLC.

This educational activity is an archive of the live symposium held on January 29, 2026.

Target Audience

This educational activity is directed toward thoracic oncologists, medical oncologists, pathologists, nurse practitioners, physician assistants, nurses, and other health care providers involved in managing resectable, early-stage NSCLC.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Assess key findings from pivotal clinical trials evaluating neoadjuvant, adjuvant, and perioperative immunotherapy for resectable, early-stage, non–small cell lung cancer (NSCLC)
• Evaluate the latest evidence for the use of targeted therapies for EGFR-mutant, resectable, early-stage NSCLC in the neoadjuvant and adjuvant settings
• Apply best practices for biomarker testing to guide personalized selection of perioperative systemic therapy in patients with NSCLC
• Implement multidisciplinary strategies to mitigate treatment-related toxicities associated with perioperative immunotherapies and EGFR-targeted tyrosine kinase inhibitors